zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2012-9-2-4zdor-1246Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСОВРЕМЕННЫЕ ВОЗМОЖНОСТИ И ПОДХОДЫ К ЛЕЧЕНИЮ САХАРНОГО ДИАБЕТА ТИПА 2MODERN MEANS AND APPROACHES TO TREATMENT FOR DIABETES MELLITUS TYPE 2КаплиеваМ. П.KapliyevaM. P.noemail@neicon.ruГомельский государственный медицинский университетGomel State Medical University201228062012022327Copyright © Каплиева М.П., 20122012Каплиева М.П.Kapliyeva M.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1246

Лечение сахарного диабета (СД 2), направленное на достижение устойчивой компенсации заболевания по показателям тощаковой, постпрандиальной и ночной гликемии, а также гликированного гемоглобина (HbА1С), должно включать участие врача и, прежде всего, самого пациента. Важнейшим принципом этиотропного лечения СД 2 является изменение образа жизни, что включает диетотерапию и режим физической активности, которые назначаются всем без исключения больным СД 2 от момента установления диагноза и до конца активной жизни при любой схеме медикаментозного лечения СД 2, но требуют усилий воли самого пациента. Медикаментозное лечение СД 2 направлено на патогенетические звенья: преодоление инсулинорезистентности и стимуляцию эндогенной секреции инсулина, а при ее истощении применяется заместительная инсулинотерапия. Все антидиабетические препараты делятся на три основные группы: инсулинсенситизаторы - препараты против инсулинорезистентности; секретагоги - препараты, стимулирующие эндогенную секрецию инсулина и инсулины.

The treatment for diabetes mellitus (DM 2), aimed to achieve firm compensation of the disease on the indicators of fasten, postprandial and night glycemia, as well as glycohemoglobin (HbА1С) must include the participation of the physician and, first of all, the patients themselves. The most important principle of DM 2 etiotropic treatment is a changed lifestyle that includes dietotherapy and physical activity mode. They are prescribed to all DM 2patients without exception since the moment of diagnosis and until the end of active life in any scheme of medical DM 2 treatment, but requires a lot of patients` effort. The DM 2 treatment is concentrated on patogenetical section: to overcome insulin resistance and stimulate endogen insulin secretions, but in case of its exhaustion, substitutive insulin therapy is used. All antidiabetic medicines are divided into three main groups: insulin sensitisers used for insulin resistance; secretagogue which stimulate insulin secretion and insulines.

сахарный диабетгипогликемияосложнениякомпенсацияинкретиныглюкагоноподобный полипептид-1diabetes mellitushypoglycemiacomplicationscompensationincretinsglucogon-like peptide-1ReferencesInternational Diabetes Federation. IDF Diabetes Atlas. 4th ed. Brussels, Belgium: International Diabetes Federation, 2009. - http://www.idf.org/diabetesatlas, accessed: 13.02.2012.International Diabetes Federation. IDF Diabetes Atlas. 4th ed. Brussels, Belgium: International Diabetes Federation, 2009. - http://www.idf.org/diabetesatlas, accessed: 13.02.2012.US Department of Health and Human Services, National Diabetes Information Clearin house // National Diabetes Statistics. - 2007. - NIH Publication, № 08-3892.US Department of Health and Human Services, National Diabetes Information Clearin house // National Diabetes Statistics. - 2007. - NIH Publication, № 08-3892.Holman, R. R. Diabetes Res Clin Pract / R. R. Holman // Endocrinology and Metabolism. - 1998. - № 40, Suppl 1. - P. 21-25.Holman, R. R. Diabetes Res Clin Pract / R. R. Holman // Endocrinology and Metabolism. - 1998. - № 40, Suppl 1. - P. 21-25.Diabetic Medicine / F. J. Snoek [et al.] // Diabetes Care. - 2010. - Vol. 39. - P. 99-102.Diabetic Medicine / F. J. Snoek [et al.] // Diabetes Care. - 2010. - Vol. 39. - P. 99-102.Association of glycaemia with marcovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study / I. M. Stratton [et al.] // BMJ. - 2000. - Vol. 321. - P. 405-412.Association of glycaemia with marcovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study / I. M. Stratton [et al.] // BMJ. - 2000. - Vol. 321. - P. 405-412.Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE and VA / S. Skyler [et al.] // Diabetes Trials Diabetes Care. - 2009. - Vol. 32(1). - P. 187-192.Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE and VA / S. Skyler [et al.] // Diabetes Trials Diabetes Care. - 2009. - Vol. 32(1). - P. 187-192.Subclinical states of glucose intolerance and risk of death in the US / S. Saydah [et al.] // Diabetes Care. - 2001. - Vol. 24. - P. 447-453.Subclinical states of glucose intolerance and risk of death in the US / S. Saydah [et al.] // Diabetes Care. - 2001. - Vol. 24. - P. 447-453.Monnier, L. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA1C / L. Monnier, H. Lapinski, C. Collette // Diabetes Care. - 2003. - Vol. 26. - P. 881-885.Monnier, L. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA1C / L. Monnier, H. Lapinski, C. Collette // Diabetes Care. - 2003. - Vol. 26. - P. 881-885.Consensus of Diabetes Mellitus Treatment // D. M. Nathan [et al.] // Diabetes Care. - 2008. - Vol. 31(1). - P. 173-175.Consensus of Diabetes Mellitus Treatment // D. M. Nathan [et al.] // Diabetes Care. - 2008. - Vol. 31(1). - P. 173-175.Accotiation of Hypoglycemia and Cardiac Ischemia / L. C. Desousza [et al.] // Diabetes Care. - 2003. - Vol. 26. - P. 1458.Accotiation of Hypoglycemia and Cardiac Ischemia / L. C. Desousza [et al.] // Diabetes Care. - 2003. - Vol. 26. - P. 1458.Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain / E. Marrett [et al.] // Diabetes, Obesity and Metabolism. - 2009. - Vol. 11. - P. 1138-1144.Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain / E. Marrett [et al.] // Diabetes, Obesity and Metabolism. - 2009. - Vol. 11. - P. 1138-1144.Baggio, L. L. Biology of incretins: GLP-1 and GIP / L. L. Baggio, D. J. Drucker // Gastroenterology. - 2007. - Vol. 132. - P. 2131-2157.Baggio, L. L. Biology of incretins: GLP-1 and GIP / L. L. Baggio, D. J. Drucker // Gastroenterology. - 2007. - Vol. 132. - P. 2131-2157.Drucker, D. J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis / D. J. Drucker // Mol Endocrinol. - 2003. - Vol. 17. - P. 161-171.Drucker, D. J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis / D. J. Drucker // Mol Endocrinol. - 2003. - Vol. 17. - P. 161-171.Holst, J. J. The physiology of glucagon-like peptide 1 / J. J. Holst // Physiol Rev. - 2007. - Vol. 87. - P. 1409-1439.Holst, J. J. The physiology of glucagon-like peptide 1 / J. J. Holst // Physiol Rev. - 2007. - Vol. 87. - P. 1409-1439.Holst, J. J. The incretin system and its role in type 2 diabetes mellitus / J. J. Holst, T. Vilsboll, C. F. Deacon // Mol Cell Endocrinol. - 2009. - Vol. 297. - P. 127-136.Holst, J. J. The incretin system and its role in type 2 diabetes mellitus / J. J. Holst, T. Vilsboll, C. F. Deacon // Mol Cell Endocrinol. - 2009. - Vol. 297. - P. 127-136.Skyler, J. S. Strategies in diabetes mellitus: start of a new era / J. S. Skyler // Postgrad. Med. - 2009. - Vol. 89. - P. 45-58.Skyler, J. S. Strategies in diabetes mellitus: start of a new era / J. S. Skyler // Postgrad. Med. - 2009. - Vol. 89. - P. 45-58.Deacon, C. F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review / C. F. Deacon // Diabetes, Obesity and Metabolosm. - 2011. - Vol. 13. - P. 7-18Deacon, C. F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review / C. F. Deacon // Diabetes, Obesity and Metabolosm. - 2011. - Vol. 13. - P. 7-18

The authors declare that there are no conflicts of interest present.